Branched-chain amino acid metabolism in cancer

Purpose of review The current review aims to provide an update on the recent biomedical interest in oncogenic branched-chain amino acid (BCAA) metabolism, and discusses the advantages of using BCAAs and expression of BCAA-related enzymes in the treatment and diagnosis of cancers. Recent findings An accumulating body of evidence demonstrates that BCAAs are essential nutrients for cancer growth and are used by tumors in various biosynthetic pathways and as a source of energy. In addition, BCAA metabolic enzymes, such as the cytosolic branched-chain aminotransferase 1 (BCAT1) and mitochondrial branched-chain aminotransferase 2, have emerged as useful prognostic cancer markers. BCAT1 expression commonly correlates with more aggressive cancer growth and progression, and has attracted substantial scientific attention in the past few years. These studies have found the consequences of BCAT1 disruption to be heterogeneous; not all cancers share the same requirements for BCAA metabolites and the function of BCAT1 appears to vary between cancer types. Summary Both oncogenic mutations and cancer tissue-of-origin influence BCAA metabolism and expression of BCAA-associated metabolic enzymes. These new discoveries need to be taken into consideration during the development of new cancer therapies that target BCAA metabolism.

[1]  D. Sabatini,et al.  Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway , 2016, Science.

[2]  F. Janku,et al.  Targeting isocitrate dehydrogenase (IDH) in cancer. , 2016, Discovery medicine.

[3]  A. Kimmelman,et al.  Metabolic Interactions in the Tumor Microenvironment. , 2017, Trends in cell biology.

[4]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[5]  C. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[6]  S. Shiozawa,et al.  Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study. , 2016, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[7]  E. Cuyás,et al.  Germline BRCA 1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis : evidence for metformin-based “ starvation ” strategies in BRCA 1 carriers , 2017 .

[8]  M. Wong,et al.  The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target. , 2015, American journal of cancer research.

[9]  David H. Murray,et al.  A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia , 2016, Clinical and Translational Gastroenterology.

[10]  G. Kong,et al.  DOT 1 L cooperates with the c-Myc-p 300 complex to epigenetically derepress CDH 1 transcription factors in breast cancer progression , 2015 .

[11]  Minoru Terashima,et al.  DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines. , 2016, Biochimie.

[12]  C. Guillemette,et al.  BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism , 2015, Oncotarget.

[13]  G. Kong,et al.  DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression , 2015, Nature Communications.

[14]  Rainer König,et al.  BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1 , 2013, Nature Medicine.

[15]  J. Locasale,et al.  Glutamine Metabolism in Cancer: Understanding the Heterogeneity. , 2017, Trends in cancer.

[16]  Ling Zhang,et al.  Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. , 2017, Biochemical and biophysical research communications.

[17]  S. McClave,et al.  Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine , 2017, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[18]  David H. Murray,et al.  A cross‐sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor‐derived DNA with CEA for detection of recurrent colorectal cancer , 2016, Cancer medicine.

[19]  J. Powell,et al.  Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond. , 2016, Advances in nutrition.

[20]  H. Yamamoto,et al.  Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  H. Carraway,et al.  Emerging therapies for acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[22]  A. Vazquez,et al.  Cancer metabolism at a glance , 2016, Journal of Cell Science.

[23]  June-Sung Lee,et al.  Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease , 2017, Medicine.

[24]  Qiyu Zhang,et al.  BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[25]  N. Kannan,et al.  Cancer progression by reprogrammed BCAA metabolism in myeloid leukemia , 2017, Nature.

[26]  B. Bridle,et al.  Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes , 2017, Immunology.

[27]  J. Moscat,et al.  Metabolism shapes the tumor microenvironment. , 2017, Current opinion in cell biology.

[28]  A. Wilkinson,et al.  Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation , 2016, Science.

[29]  E. Ananieva.  Targeting amino acid metabolism in cancer growth and anti-tumor immune response. , 2015, World journal of biological chemistry.

[30]  M. Conway,et al.  BCAA Metabolism and NH3 Homeostasis. , 2016, Advances in neurobiology.

[31]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[32]  Purushottam D. Dixit,et al.  Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers , 2016, Science.

[33]  T. Joh,et al.  Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial. , 2017, Nutrition.

[34]  Henry J. Lin,et al.  In search of druggable targets for GBM amino acid metabolism , 2017, BMC Cancer.

[35]  D. Sabatini,et al.  Sestrin 2 is a leucine sensor for the mTORC 1 pathway , 2016 .

[36]  Mee-Sup Yoon.  The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism , 2016, Nutrients.

[37]  P. Srivastava,et al.  BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases , 2017, Nature Communications.

[38]  M. V. Vander Heiden,et al.  Nature and Nurture: What Determines Tumor Metabolic Phenotypes? , 2017, Cancer research.

[39]  H. Baba,et al.  Prognostic Impact of Visceral Fat Amount and Branched-Chain Amino Acids (BCAA) in Hepatocellular Carcinoma , 2015, Annals of Surgical Oncology.

[40]  A. Schneeweiss,et al.  The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer , 2017, Oncogene.

[41]  D. Sabatini,et al.  Sestrin2 is a leucine sensor for the mTORC1 pathway , 2016, Science.

[42]  E. Cuyás,et al.  Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based “starvation” strategies in BRCA1 carriers , 2016, Oncotarget.

[43]  Takuji Tanaka,et al.  Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model , 2017, Oncotarget.

[44]  Y. Takei,et al.  Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. , 2015, Journal of nutritional science and vitaminology.

[45]  S. Selvan,et al.  Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. , 2016, Current cancer drug targets.

[46]  J. Powell,et al.  Cytosolic Branched Chain Aminotransferase (BCATc) Regulates mTORC1 Signaling and Glycolytic Metabolism in CD4+ T Cells* , 2014, The Journal of Biological Chemistry.

[47]  Prasenjit Dey,et al.  Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer , 2017, Nature.